PPAR gamma Agonists – Plant Compounds

PPAR gamma Agonists – Plant Compounds

The nuclear receptor peroxisome proliferator activated receptor-gamma (PPARg) controls adipocyte differentiation, as well as lipid metabolism and insulin sensitivity. As a result, PPARg is a promising candidate gene for a variety of human diseases, such as obesity and type 2 diabetes. Hyperglycemia...

Full description

Bibliographic Details
Main Authors:	Anil Kumar Moola, Shobana G., C. Janani
Format:	Article
Language:	English
Published:	"Vikol publishing" ST Kolesnichenko V.V. 2023-12-01
Series:	Journal of Stress Physiology & Biochemistry
Subjects:	ppar gamma type 2 diabetes natural products
Online Access:	http://www.jspb.ru/issues/2023/N4/JSPB_2023_4_163-177.pdf

Similar Items

Natural Compound 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al from <i>Momordica charantia</i> Acts as PPARγ Ligand
by: Nur Adelina Ahmad Noruddin, et al.
Published: (2021-05-01)

Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences
by: Umesh D. Laddha, et al.
Published: (2020-08-01)

Molecular docking studies on potential PPAR-γ agonist from Rhizophora apiculata
by: Gurudeeban Selvaraj, et al.
Published: (2014-07-01)

Marine Natural and Nature-Inspired Compounds Targeting Peroxisome Proliferator Activated Receptors (PPARs)
by: Enrico D’Aniello, et al.
Published: (2023-01-01)

PPAR Gamma and Viral Infections of the Brain
by: Pierre Layrolle, et al.
Published: (2021-08-01)

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
by: Sangeeta Ballav, et al.
Published: (2022-10-01)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
by: Hayley Patricia Ellis, et al.
Published: (2014-03-01)

PPAR-Gamma Activation May Inhibit the In Vivo Degeneration of Bioprosthetic Aortic and Aortic Valve Grafts under Diabetic Conditions
by: Shintaro Katahira, et al.
Published: (2021-10-01)

Obesity-Linked PPARγ Ser273 Phosphorylation Promotes Beneficial Effects on the Liver, despite Reduced Insulin Sensitivity in Mice
by: Maiara Ferreira Terra, et al.
Published: (2023-03-01)

Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds
by: Lars Porskjær Christensen, et al.
Published: (2018-09-01)

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
by: Treacy Maxwell P, et al.
Published: (2012-09-01)

Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model
by: Yuji Nakano, et al.
Published: (2020-07-01)

The Immunotherapeutic Effects of Pentoxifylline in Type 1 Diabetic Mice and its Effects on Expressions of Peroxisome proliferator-activated receptor gamma (PPARγ) gene
by: F Malekifar, et al.
Published: (2015-05-01)

Effect of 6-Benzoyl-benzothiazol-2-one scaffold on the pharmacological profile of α-alkoxyphenylpropionic acid derived PPAR agonists
by: Aurélie Hurtevent, et al.
Published: (2020-01-01)

Low Expression Levels of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gastric Cancer and its Relationship with Tumor Progression
by: Gholam Basati, et al.
Published: (2017-09-01)

Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist
by: Hiroyuki Miyachi
Published: (2023-02-01)

The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
by: Pallavi R. Devchand, et al.
Published: (2018-10-01)

Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism
by: Rishabh Khera, et al.
Published: (2022-01-01)

An Asymmetric Synthesis of PPAR-? Agonist Navaglitazar from (+)-Methyl (2S,3R)-3-(4-methoxyphenyl)glycidate
by: John R. Rizzo, et al.
Published: (2006-09-01)

Potential of Natural Products in the Inhibition of Adipogenesis through Regulation of PPARγ Expression and/or Its Transcriptional Activity
by: Shi Feng, et al.
Published: (2016-09-01)

Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPARγ
by: Ma L, et al.
Published: (2016-05-01)

Structural Basis for the Regulation of PPARγ Activity by Imatinib
by: Jun Young Jang, et al.
Published: (2019-10-01)

Association of Metformin Pharmacogenetic with a Single Amino Acid Alteration in Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Genein Patients with Polycystic Ovary Syndrome
by: Fatemeh Jafari, et al.
Published: (2019-12-01)

Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway
by: Jun-Qing Jin, et al.
Published: (2021-10-01)

Effects of peroxisome proliferator activated receptor gamma (PPARγ) agonist on fasting model applied neuron cultures
by: Pınarbaşı Arzu, et al.
Published: (2021-10-01)

Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma
by: Alexandre Vallée, et al.
Published: (2017-05-01)

Peroxisome proliferator activated receptor gamma controls mature brown adipocyte inducibility through glycerol kinase
by: Lasar, David, et al.
Published: (2018)

The potential of natural products for targeting PPARα
by: Daniela Rigano, et al.
Published: (2017-07-01)

Peroxisome proliferator activated receptor gamma polymorphism Pro12Ala in polycystic ovary syndrome (PCOS) of South Indian Population
by: Raichel Jacob, et al.
Published: (2016-05-01)

Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex
by: Xinran Ma, et al.
Published: (2018-08-01)

PPARγ Agonists: Emergent Therapy in Endometriosis
by: Alexandre Vallée, et al.
Published: (2021-06-01)

The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
by: David Aguilar-Recarte, et al.
Published: (2021-08-01)

PPARβ/δ Agonist Alleviates Diabetic Osteoporosis via Regulating M1/M2 Macrophage Polarization
by: Miao Chen, et al.
Published: (2021-11-01)

CYP2C19 Contributes to THP-1-Cell-Derived M2 Macrophage Polarization by Producing 11,12- and 14,15-Epoxyeicosatrienoic Acid, Agonists of the PPARγ Receptor
by: Hee Young Cho, et al.
Published: (2023-04-01)

Peroxisome Proliferator-Activated Receptor-α (<i>PPARα</i>) Expression in a Clinical Population of Pakistani Patients with Type 2 Diabetes and Dyslipidemia
by: Maria Arif, et al.
Published: (2022-09-01)

Studies on the contribution of PPAR Gamma to tuberculosis physiopathology
by: Ariana Díaz, et al.
Published: (2023-04-01)

Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo
by: Lingyao Du, et al.
Published: (2017-05-01)

Optimized Structure-based Methodology for Studying PPARγ Partial Agonists
by: Merilin Al Sharif, et al.
Published: (2018-03-01)

A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue
by: Ren Sheng, et al.
Published: (2024-03-01)

The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders
by: Jesús Porcuna, et al.
Published: (2021-09-01)